ArticleLuminescence : the journal of biological and chemical luminescence2026
Spectrofluorimetric Determination of Silodosin Using NBD-Cl Reagent: Applications to Capsules and Content Uniformity Testing.
Article in Luminescence : the journal of biological and chemical luminescence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Silodosin (SDN) works by specifically blocking alpha-1 adrenergic receptors, with a strong preference for the α1A type and clinically approved for alleviating the symptoms associated with benign prostatic hyperplasia in adult patients. The medication is precisely quantified using a novel, affordable spectrofluorimetric strategy in this paper. The strategy uses a fluorogenic reagent (4-chloro-7-nitrobenzofurazan, NBD-Cl) to create a fluorescent compound called "SDN-NBD" when it reacts with SDN. Optimal fluorescence emission was recorded at 534.7 nm (excitation: 473.4 nm) after systematic refinement of reaction variables, including pH, temperature, and NBD-Cl concentration. The approach exhibited remarkable linearity throughout a spectrum of 40-750 ng/mL (R
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.